Comments and feedback from listeners are always welcome!
If you enjoy listening to the podcast, please do share it on social media (we’re @TargetsPodcast on Twitter) and/or consider leaving a review or rating on iTunes. With 400,000+ podcasts competing for ears, we rely on listeners to help us reach a wider audience.
Below is a sample of some of the reviews and feedback we’ve received. If we’ve missed a review you’ve done (and you’d like us to share it), do send us a note. We’re always keen to hear what you like (or don’t like) and what we could do better. Thanks for your support!
And if you want to find some more science podcasts, do check out “A Big List of Science Podcasts“ collated by biomedical optics and sensing researcher Lewis E. Mackenzie on his website.
The Memorial Sloan Kettering (MSK) Cancer Center Library also has a LibGuide that lists science podcasts that may be of interest to the MSK Community. This is publicly accessible, so do check it out.
Apple iTunes Reviews
Novel Targets – Science worth your time by YFacio
“Fascinating, short, succinct. The information is presented clearly and in a way that anyone can understand. Having had cancer, I can say that learning more about it and what we are doing to fight it is hopeful. Thanks to Novel Targets for bringing new information to the masses.”
Great to Hear from Leaders in Science by kirk802
“These podcasts are excellent. Reading medical journal articles can be (is) numbing after a while. The recent podcasts are excellent in bringing true experts who can and do cut through to the key points and topics (helped along by excellent questions from Peter).”
Concise, Informative and anything but novel by Sarah Arrow
“If you’re into medicine or biotech then you need to subscribe to this podcast. This is a no spoilers review, and I’m impressed with the professionalism and knowledge shared in the first two episodes.”
Most Comprehensive Science and Biotech Podcast by NGs Dad
“This podcast is an in-depth look at burgeoning biotech research and how it affects the present medical application and treatments. Th podcast provides in-depth science and Mechanisms of Action to offer explanations and rational as to why drugs are being targeted to certain targets. Providing interviews with KOLs and PIs in the field, adds to the significance, validity and currency of these issues. For the Scientist, Biotech Officer, Investor and Enthusiast, I highly recommend Novel Targets.”
11 Podcasts for Savvy Pharma Marketers
Thanks to MNG Direct (@mngdirect) for giving us a mention in their blog post on podcasts to listen. We listen to some of these shows too! Do check out their post on “11 Podcasts for Savvy Pharma Marketers.” Here’s what they had to say about us:
If you enjoy listening to NPR on Saturday afternoons, you’ll like Novel Targets for the great production value. Each 30- to 40-minute episode goes deep on a specific topic and includes interviews with multiple global thought leaders. The high-science information is presented in a straightforward and helpful way that will give you context no matter what therapeutic area you’re in.
— F Haroun, MD (@Cancer_talks) July 6, 2017
— Steven Dublin (@sndublin) July 6, 2017
Fav quote: When it comes to shaping the future there are ppl who let it happen, ones who make it happen and those who wondered what happened
— Kristina Kakalacheva (@kpuckk) July 5, 2017
— James L Gulley MDPhD (@gulleyj1) May 21, 2017
— Paul D. Rennert (@PDRennert) May 5, 2017
Right, that was another big takeaway from this great podcast: cancer immunotherapy could be the very definition of “*personalized* medicine”
— David Maizenberg (@biologypartners) May 5, 2017
February 2017 Review by @ohmsonite
— ohmsonite (@ohmsonite) February 1, 2017
Excerpt from @ohmsonite review. My favs: episode 5 : Titans of Adoptive Cell Therapy (Dr Carl June & Dr Rosenberg duke it out, in the most friendly and professional way about TCR and CAR T therapies), episode 11 (Dan Chen & Ira Mellman talk about the world famous cancer immunity cycle).
Sometimes I go back and listen numerous times during my commute and frankly, I learn something new each time. If you like them, make sure you subscribe to them in iTunes and give them the reviews they so very deserve.
— Marseille Immunopole (@Immunopole) November 2, 2016
“We are at the beginning of a new era…of developing effective therapies” – George Coukos, Ludwig Lausanne director https://t.co/OHMZW6FCe4
— Ludwig Cancer (@Ludwig_Cancer) November 3, 2016
— Miguel Perales M.D. (@DrMiguelPerales) November 30, 2016
— Brad Loncar (@bradloncar) August 17, 2016
— RegenerativeMedicine (@CryoportConsult) August 17, 2016
— Oleg Kolupaev (@okolupaev) August 17, 2016
In a June 23, 2016 post on Adventures In Living Terminally Optimistic Blog, patient advocate, and stage 4 colorectal cancer patient, Tom Marsilje, PhD (@CurrentincurSci) picked up on the message of “hope” in the podcast.
In several blog posts, Tom shared his excitement about the potential breakthrough in microsatellite stable (MSS) CRC where responses were seen with a combination of two drugs, neither of which worked on their own previously. Tom’s review of the podcast highlights the importance of patient education.
— Michael Sola (@michaelsola) June 23, 2016
— UbiVac (@UbiVac) May 21, 2016
— Myeloma Teacher (@MyelomaTeacher) May 20, 2016
— (((DieterHovekamp))) (@dhovekamp42) April 30, 2016
Sticking w/ Dr Chen’s cycling analogy-I’m more excited for S2 Novel Targets than the 2016 Tour d’France – great E11! https://t.co/WICQyQikMO
— Andy Kinley (@AndyKinley) April 29, 2016
Novel Targets made Luke Timmerman’s Top 10 list on Forbes
Thanks for the shout-out Luke!
— Luke Timmerman (@ldtimmerman) April 24, 2016
Feedback on Season 1
Following Episode 10: New Horizons in Hematology, a CLL patient sent an email to say:
“I am an avid consumer of research and interviews in CLL. This is truly one of the best interviews I’ve have ever read/heard. Very comprehensive.”
An important takeaway from the feedback we’ve received from cancer patients is that many have a high-level of knowledge about their disease. They want to be informed and educated about the latest research and what new treatment options may be on the horizon. They never know when they might relapse or progress and be in need a clinical trial that offers renewed hope.
Can’t speak highly enough about @TargetsPodcast . Always educational AND great production
— PropThink (@PropThinker) November 27, 2015
— Myeloma Teacher (@MyelomaTeacher) November 25, 2015
— Oleg Kolupaev (@okolupaev) November 25, 2015
Thank you @TargetsPodcast for your excellent work illuminating immunotherapy for the masses.
— Coleman Kennedy (@biotechkcw) September 22, 2015
— Miloš Miljković (@miljko) July 11, 2017
— Krishna Komanduri (@drkomanduri) August 21, 2015
— NovelTargets Podcast (@TargetsPodcast) September 23, 2015
— Laura Strong (@scientre) September 22, 2015
— GRACE (@cancerGRACE) June 16, 2015
— AnneMarie Ciccarella (@chemobrainfog) April 30, 2015